Oral pharmaceutical formulations containing 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives
AssigneeCadrenal Therapeutics, Inc.
InventorsDavid Maloney, Henry Flanner, Matthew Boxer
Life of this patent
Estimating the term…
Loading patent…
AssigneeCadrenal Therapeutics, Inc.
InventorsDavid Maloney, Henry Flanner, Matthew Boxer
Estimating the term…
Provided are pharmaceutical formulations comprising 4-((2-hydroxy-3-methoxybenzyl)amino)-benzenesulfonamide 12-LOX inhibitors with improved solubility for oral administration. Also provides are pharmaceutical formulations comprising selective 12-LOX inhibitors with high drug loading of 30% or more amorphously dispersed in selected from vinylpyrollidone-vinyl acetate copolymers (Kollidon VA64), amino methacrylate copolymer (Eudragit EPO), Hydroxypropylmethylcellulose E3 (HPMC E3), or a combination thereof and make up 40 to 80% of the total solid content of the formulation. The formulation alternatively contains additives such as surfactants (sodium lauryl sulfate), crystal inhibitors, or pH modifiers up to 20% of the total solid content of the formulation.
A pharmaceutical formulation comprising:
A pharmaceutical formulation comprising:
A pharmaceutical formulation comprising:
A pharmaceutical formulation comprising a compound of Formula (I):
Dependencies are inferred from the claim text.